ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Lowered by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. reduced its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,888,238 shares of the company's stock after selling 254,617 shares during the quarter. ORIC Pharmaceuticals accounts for about 1.3% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 20th largest holding. Frazier Life Sciences Management L.P. owned about 5.51% of ORIC Pharmaceuticals worth $31,378,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in ORIC Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock valued at $5,788,000 after acquiring an additional 103,237 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of ORIC Pharmaceuticals by 6.9% in the 4th quarter. Wellington Management Group LLP now owns 186,430 shares of the company's stock valued at $1,504,000 after purchasing an additional 12,042 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of ORIC Pharmaceuticals in the 4th quarter valued at about $1,729,000. Sphera Funds Management LTD. lifted its position in shares of ORIC Pharmaceuticals by 112.8% during the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock worth $2,205,000 after purchasing an additional 144,817 shares during the last quarter. Finally, NEOS Investment Management LLC acquired a new position in ORIC Pharmaceuticals in the fourth quarter worth about $367,000. Institutional investors and hedge funds own 95.05% of the company's stock.

ORIC Pharmaceuticals Price Performance

Shares of NASDAQ ORIC traded up $0.40 during mid-day trading on Monday, hitting $6.35. The company had a trading volume of 911,637 shares, compared to its average volume of 657,474. ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.67. The stock has a market cap of $451.41 million, a price-to-earnings ratio of -3.49 and a beta of 1.37. The firm's 50 day simple moving average is $5.41 and its two-hundred day simple moving average is $7.79.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.09. Equities analysts forecast that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ORIC shares. HC Wainwright restated a "buy" rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, May 5th. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Thursday, March 20th. Finally, Oppenheimer dropped their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $19.17.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.